Considering the number of severe maternal and fetal complications that can result from untreated hypertension, ob/gyns must be vigilant about recognizing the chronic form of the disease. Anything less puts your patients and you in harm's way.
Tebipenem HBr cUTI trial ends early after meeting efficacy goals
May 28th 2025GSK and Spero Therapeutics announced that the phase 3 PIVOT-PO trial for tebipenem HBr, a potential first oral carbapenem for cUTIs in the United States, was stopped early because of positive efficacy results.
Read More